Amgen After ASCO: Questions Remain On Lumakras, Bemarituzumab
Executive Summary
Remaining questions after ASCO include whether Lumakras (sotorasib) might work in first-line NSCLC with certain co-mutations and if ocular toxicities will hamper bemarituzumab in gastric cancer.
You may also be interested in...
Keeping Track: New Uses For Opdivo, Trodelvy; Nextstellis Introduces A Novel Estrogen
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Amgen Paying $1.9bn For Five Prime And Its Gastric Cancer Antibody
Five Prime’s Phase III-ready bemarituzumab could offer significant revenue for Amgen, particularly in Asia, but analysts ask if the buyout is a precursor to greater deal making by Amgen.
Amgen’s KRAS G12C Inhibitor Shows Deep, Durable Efficacy In Lung Cancer
Results from the Phase II CodeBreak 100 study of sotorasib presented at the World Conference on Lung Cancer were included in Amgen’s applications for approvals in the US, EU and other countries.